Literature DB >> 19593637

E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor.

Loredana Mauro1, Michele Pellegrino, Rosamaria Lappano, Adele Vivacqua, Francesca Giordano, Maria Grazia Palma, Sebastiano Andò, Marcello Maggiolini.   

Abstract

In the present study, we evaluated the ability of 4-hydroxytamoxifen (OHT) and epidermal growth factor (EGF) to regulate homotypic adhesion in MCF7 breast cancer cells. Our results demonstrate that OHT and EGF activate the E-cadherin promoter, increase E-cadherin mRNA and protein expression and enhance homotypic aggregation of MCF7 cells. Interestingly, an ERalpha and EGFR cross-talk is involved in the E-cadherin expression by OHT and EGF, as demonstrated by knocking down either receptor. On the basis of our findings, the well-established cross-talk between ERalpha and EGFR could be extended to the modulation of E-cadherin expression by OHT and EGF. Thus, the potential ability of tamoxifen to induce cell-cell aggregation may contribute to the biologic response of pharmacologic intervention in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593637     DOI: 10.1007/s10549-009-0456-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.

Authors:  Hilda Wong; Silvia Lau; Polly Cheung; Ting Ting Wong; Andrew Parker; Thomas Yau; Richard J Epstein
Journal:  BMC Cancer       Date:  2014-11-10       Impact factor: 4.430

2.  OIP5-AS1 contributes to tumorigenesis in hepatocellular carcinoma by miR-300/YY1-activated WNT pathway.

Authors:  Yu Wang; Lei Dou; Yun Qin; Huiyuan Yang; Peng Yan
Journal:  Cancer Cell Int       Date:  2020-09-09       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.